Reuters reported Tuesday that Pfizer is considering cutting its workforce as "part of a comprehensive review of its operations."
The giant pharmaceutical company, which has been hit with concerns about the safety of its arthritis medications Celebrex and Bextra, said the review would involve its pharmaceutical, animal health and consumer product units, according to the news report.
Pfizer spokesman Paul Fitzhenry told Reuters the actual number of positions under consideration in the workforce reduction had not yet been decided and that it would be "premature to speculate" on the numbers.
Earlier on Tuesday, Reuters cited a research report from Lehman Brothers that speculated Pfizer is considering reducing its sales force by up to 30 percent. ""Pfizer will be restructuring its sales and marketing teams," Lehman analyst Tony Butler said in the research note, as reported by Reuters.